Trial Profile
A Phase 2, Randomized, Open-Label Study of Sofosbuvir/GS-5885 Fixed Dose Combination +/- Ribavirin in Subjects With Chronic Genotype 1 HCV Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms LONESTAR
- Sponsors Gilead Sciences
- 03 Dec 2016 Results of post treatment resistance analysis (n=51) using data from this and four other trials (NCT01260350, NCT01701401, NCT01768286, NCT01851330) published in the Journal of Hepatology
- 21 Jan 2014 Status changed from active, no longer recruiting to completed as reported by the ClinicalTrials.gov record.
- 08 Nov 2013 Results published in the Lancet.